TERN PLC

Regulatory Filings • Dec 5, 2019

Tern PLC (TERN) 04-Dec-2019 / 07:00 GMT/BST Dissemination of a RegulatoryAnnouncement that contains inside information according to REGULATION (EU) No 596/2014 (MAR), transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.

Thisannouncement contains inside informaon for the purposes of Arcle 7 ofEU Regulaon 596/2014. 4 December 2019

Tern Plc("Tern" or the "Company") New commercial order forFundamentalVR

Tern Plc (AIM: TERN), the investment company specialising in the Internet of Things ("IoT"), is pleased to announce that FVRVS Limited ("FundamentalVR"),aleadingvirtual reality ("VR") trainingand dataanalysis technology pla4orm,and one ofTern's exisng por4olio companies, has secured asignificant new contract (£0.5 million) to create a Virtual Reality Hapc Simulaon pla4orm fora new customer, which isa global pharmaceucal company ("the Client").

This is the first of a planned series of virtual reality simulaons to be designed by FundamentalVR to support the Client's ambions to accelerate the safe and compliant use of their products. This order to configure the Fundamental pla4orm fora surgical procedure is expected to be completed during 2020.FundamentalVR's technology is now being used byan array of customergroups including:

• Clinics/ medical centres
• Device companies
• Pharmaceucal companies

FundamentalVR'saward winning pla4orm combines immersive VR with cu<ng-edge hapcs (the sense of touch) to create low-cost, measurable and scalable simulaon experiences. FundamentalVR's unique technology provides surgeons and medical professionals with a new and be?er way of developing their skills. Importantly, it also provides companies with data on skills and usage of their products, enabling acceleraon of the safe and compliant use of their products.

Tern CEO, Al Sisto, said, "FundamentalVR connues to expand its market presence through its complementary hapc-based simulaon pla4orms and we congratulate the FundamentalVR team on this addional contract win.FundamentalVR's award-winning technology will be employed by this pharmaceucal company to drive the uptake of its products, highlighng the broad array of medical markets available to our por4olio company. Importantly, the FundamentalVR team is ideally posioned to execute on this potenal mul-phase project following its recent fundraise which saw investment from well-regarded instuons. We look forward to reporng on the future growth of this excing business, as well as our other por4olio companies."

**ENDS**

Enquiries
Tern plc	Via Newgate Communicaons
Al Sisto, CEO
Sarah Payne,Finance Director
Allenby Capital Limited	Tel: 0203 328 5656
(Nomad and Joint broker)
David Worlidge/Alex Brearley
Whitman Howard	Tel: 020 7659 1234
(Joint broker) Nick Lovering/ChristopherFurness
Newgate Communica+ons	Tel: 020 3757 6880
PR
Elisabeth Cowell/Megan Kovach

TIDM: TERN LEICode: 2138005F87SODHL9CQ36 Sequence No.: 33120 EQS News ID: 927543

End ofAnnouncementEQS News Service